<DOC>
	<DOCNO>NCT00113009</DOCNO>
	<brief_summary>This phase II , multicenter , randomize , double-blind , placebo-controlled trial subject intermittent claudication ( IC ) randomize receive single treatment VLTS-934 ( 84 mL , total 420 mg poloxamer 188 ) placebo ( 84 mL saline ) administer 21 intramuscular ( IM ) injections 2 mL , bilaterally low extremity one procedure evaluate safety , tolerability , potential activity VLTS-934 compare saline placebo .</brief_summary>
	<brief_title>Trial VLTS-934 Subjects With Intermittent Claudication Secondary Peripheral Arterial Disease</brief_title>
	<detailed_description>This Phase II , multicenter , randomize , double-blind , placebo-controlled trial subject IC randomize receive single treatment VLTS-934 ( 84 mL , total 420 mg poloxamer 188 ) placebo ( 84 mL saline ) administer 21 intramuscular ( IM ) injections 2 mL , bilaterally low extremity one procedure evaluate safety , tolerability , potential activity VLTS-934 compare saline placebo .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Intermittent Claudication</mesh_term>
	<criteria>Diagnosis peripheral arterial disease legs History exercise limiting symptom Lower limb revascularization surgery 2 month study entry Diagnosis critical limb ischemia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>March 2006</verification_date>
	<keyword>Peripheral arterial disease</keyword>
</DOC>